Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination therapy for non‑small cell lung cancer.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border procurement, ensuring timely delivery and product integrity.

Nintedanib is employed to treat fibrotic lung conditions and as part of combination regimens for certain cancers, acting on pathways that drive fibroblast activity and tumor angiogenesis. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve pulmonary capacity and delays worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with standard chemotherapy.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often manageable with dietary measures. - Nausea: mild to moderate feeling of queasiness. - Vomiting: occasional episodes of stomach emptying. - Elevated liver enzymes: increase in ALT/AST observed in laboratory tests.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring and possible discontinuation. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: rare cases of arterial thromboembolism.

When prescribing Nintedanib, clinicians should observe several precautionary measures to ensure patient safety. - Liver function monitoring: assess ALT, AST, and bilirubin before treatment and periodically thereafter. - Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea promptly. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use due to unknown fetal risk; discontinue if pregnancy occurs. - Contraindications: do not use in patients with severe hepatic impairment. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nintedanib can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure and toxicity. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels. - P-glycoprotein substrates (e.g., digoxin): potential for altered concentrations. - Acid‑reducing agents (e.g., proton pump inhibitors): may reduce absorption, monitor efficacy.